logo-loader

Patrys Limited granted Australian anti-cancer treatment patent

Last updated: 15:20 18 Nov 2013 AEDT, First published: 14:20 18 Nov 2013 AEDT

no_picture_pai

Patrys Limited (ASX: PAB), should push higher after being granted a second Australian patent for its clinical anti-cancer product PAT-SM6.

The Australian Patent Office has issued the official “Notice of Grant” for “Novel glycosylated peptide target in neoplastic cells”.

This patent is one of a series of applications submitted to cover the PAT-SM6 product, target and mechanism of action, taking protection through to 2027, with orphan designation granted previously in in both Europe and the US.

The claims in this patent cover the PAT-SM6 antibody and binding fragments and their methods of use for treatment of various cancers including multiple myeloma.

To date, seven patents in the PAT-SM6 family have been granted in various jurisdictions including Europe, Japan, the US and Australia.

Patrys is now in a solid position to capitalise on their novel antibody product, and recently announced it will partner with Onyx Pharmaceuticals to follow up clinical trials involving PAT-SM6 in combination with carfilzomib, for patients with relapsed and refractory multiple myeloma.

 

Proactive Investors Australia is the market leader in producing news, articles and research reports on ASX “Small and Mid-cap” stocks with distribution in Australia, UK, North America and Hong Kong / China.

Patrys secures US patents for antibody technology

Patrys Ltd (ASX:PAB) managing director and CEO Dr James Campbell talks with Proactive’s Elisha Newell about two new patents that advance protection for the company’s antibody technology through to 2039. The first patent, co-filed with Yale University, is the first US patent to be granted...

on 17/4/23